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Screening of flavonoid aglycons’ metabolism mediated 
by the human liver cytochromes P450
Biological effects of flavonoids have been extensively stud-
ied in the last 80 years. As flavonoids represent a rather 
large group of compounds, data on metabolic biotransfor-
mations of these compounds is relatively limited to those 
well studied. The objective of this study was to screen the 
metabolism of 30 selected flavonoid aglycons mediated by 
the most relevant metabolic enzymes, human liver cyto-
chromes P450. For this purpose, in vitro experiments with 
human liver microsomes and recombinant enzymes were 
conducted. To evaluate flavonoid ś metabolism and struc-
ture of the products, high-performance liquid chromatog-
raphy coupled with high-resolution mass spectrometry 
was used. Out of 30 flavonoids, 15 were susceptible to oxi-
dative metabolism mediated by cytochromes P450. Domi-
nant reactions were aromatic hydroxylation and O-deme-
thylation, or a combination of these reactions. The dominant 
enzyme responsible for the observed metabolic reactions is 
CYP1A2, whereas other human liver cytochromes P450, 
namely, CYP2C19, CYP2D6, CYP2E1 and CYP3A4, contribute 
to flavonoid metabolism to a lesser degree. These results, to 
some extent, contribute to the understanding of the meta-
bolism of constituents found in antioxidant dietary supple-
ments and their possible interactions with other xenobiotics, 
i.e., medicinal products.
Keywords: flavonoids, human liver cytochromes P450, meta-
bolism, HPLC, MS
In 1936 professor Szent-Györgyi isolated a reducing agent, co-factor in reactions of 
peroxidase and vitamin C. This agent was named vitamin P and later on was identified as 
rutin (1). To this date, more than 4000 different compounds have been identified and clas-
sified as flavonoids (2). Flavonoids are low molecular polyphenols containing benzo-γ- 
-pyrone core in their structure (Fig. 1).
A significant number of pharmacological effects of flavonoids has been described, e.g., 
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anti-inflammatory, and hepatoprotective effect (1, 3). Although the amount of available 
data on their positive health benefits based on in vitro experiments is overwhelming, there 
are differences between effects observed in vivo and in vitro (4).
To some extent, this is related to the lack of information on flavonoids’ metabolism, 
that has been characterized for a relatively small number of compounds. Major enzymes 
that contribute to the metabolism of xenobiotics, including flavonoids, are cytochromes 
P450. Cytochromes P450 participate in the metabolism of nearly ¾ of all small drugs and 
other xenobiotics. Most significant cytochrome P450 is 3A4 that participates in the meta-
bolism of over 50 % of xenobiotics, whereas flavonoids are mainly metabolized with cyto-
chrome P450 1A2 (5). Knowing the cytochrome P450 enzymes involved in the metabolism 
of flavonoids contributes to the understanding of their bioavailability, pharmacokinetics, 
and consequently pharmacodynamics, as well as potential interactions with other con-
comitantly used medications.
The data on pharmacokinetics and metabolism of flavonoids is limited (6–20). Research 
articles on the metabolism of individual flavonoid used in this study are referenced in 
Table I. These are often limited to observatory studies of induction and inhibition of cyto-
chromes P450 (21, 22). Flavonoids mainly undergo cytochrome P450 reactions of aromatic 
hydroxylation and O-demethylation (Fig. 2). 
Thus, the objective of this research was to determine human liver cytochromes P450 
involved in the metabolism of 30 selected flavonoid aglycons. The set used represents most 
commonly found flavonoid aglycons in plant species rich in polyphenols. For this purpose, 
experiments were conducted using commercially available human liver microsomes and 
recombinant cytochromes P450. Metabolism was monitored by high-performance liquid 




Methanol and formic acid (LC-MS grade) were purchased from Honeywell Specialty 
Chemicals Seelze GmbH, Germany, and Merck KGaA, Germany, resp. Ultra-pure water 
was produced using Arium comfort combined water production system from Sartorius 
AG, Germany. Flavone, flavanone, 6-hydroxyflavone, 7-hydroxyflavone, chrysin, 3,6-dihy-
droxyflavone, 3,7-dihydroxyflavone, pinocembrin, tectochrysin, apigenin, galangin, genis-
tein, pinocembrin-7-methylether, naringenin, kaempferol, sakuranetin, catechin, diosme-
tin, morin, quercetin, hesperetin, isorhamnetin, tamarixetin, rhamnetin, myricetin, and 
Fig. 1. Structures of: a) benzo-γ-pyrone, and b) flavonoid core.
a) b)
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Table I. Structural features of flavonoids used in the screening of cytochromes P450 mediated metabolisma
No. Flavonoid C5 C6 C7 C8 C2’ C3’ C4’ C5 Metabolic reaction (literature source)a
Flavones (C2–Ph, C2=C3, C4=O)
1 Acacetin OH H OH H H H OCH3 H 4'-demethylation (6)
2 Apigenin OH H OH H H H OH H 3'-hydroxylation (7–9)
3 Diosmetin OH H OH H H OH OCH3 H 4'-demethylation (10)
4 Flavone H H H H H H H H
5 6-Hydroxyflavone H OH H H H H H H
6 7-Hydroxyflavone H H OH H H H H H
7 Chrysin OH H OH H H H H H 6-hydroxylation (7–9)
8 Chrysin-dimethyl ether OCH3 H OCH3 H H H H H
9 Luteolin OH H OH H H OH OH H
10 Tangeretin OCH3 OCH3 OCH3 OCH3 H H OCH3 H
4'-demethylation (7, 
11, 12)
11 Techtocrysin OH H OCH3 H H H H H
Flavonoles (C2–Ph, C2=C3, C3–OH, C4=O)
12 3,6-Dihydroxyflavone H OH H H H H H H
13 3,7-Dihydroxyflavone H H OH H H H H H
14 Galangin OH H OH H H H H H 4'-hydroxylation (7, 13)
15 Isorhamnetin OH H OH H H OCH3 OH H
16 Kaempferol OH H OH H H H OH H 3'-hydroxylation (7, 8)
17 Morin OH H OH H OH H OH H
18 Myricetin OH H OH H H OH OH OH
19 Quercetin OH H OH H H OH OH H
20 Rhamnetin OH H OCH3 H H OH OH H
21 Tamarixetin OH H OH H H OH OCH3 H
4'-demethylation (7, 
8)
Isoflavones (C2=C3, C3–Ph, C4=O)







23 Prunetin OH H OCH3 H H H OH H 4'-demethylation (15)
Flavanones (C2-Ph, C2–C3, C4=O)
24 Flavanone H H H H H H H H
25 Hesperetin OH H OH H H OH OCH3 H
4'-demethylation (7, 
8, 20)
26 Naringenin OH H OH H H H OH H 3'-hydroxylation (7, 8)
27 Pinocembrin OH H OH H H H H H
28 Pinocembrin-7- -methylether OH H OCH3 H H H H H
29 Sakuranetin OH H OCH3 H H H OH H
Flavanole (C2–Ph, C2–C3, C3–OH, C4=O)
30 Catechin H OH H H OH OH
a Previous data on most dominant metabolic reactions of individual flavonoids reported under literature column, 
if available.
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tangeretin were purchased from Extrasynthese, France. 3,7,4’-Trihydroxyflavone, 6,7-dihy-
droxyflavone, 7,8-dihydroxyflavone, 4’-hydroxyflavone, 2’-hydroxyflavone, 5,3’,4’-trihy-
droxy-7-methoxyflavanone were obtained from TransMIT GmbH, Project Division for 
Plant Metabolites and Chemicals, Germany, and eriodictyol from Biovit Ltd., Croatia. Hu-
man liver microsomes (HLM) and recombinant cytochrome P450 expressed in baculo-
somes were obtained from Thermo Fisher Scientific, USA. Glucose-6-phosphate (G6P), 
glucose-6-phosphate dehydrogenase (G6PD) and NADP disodium salt were purchased 
from Sigma Aldrich, USA. Potassium phosphate and concentrated hydrochloric acid were 
purchased from Kemika d.d., Croatia. Acetonitrile for chromatography was purchased 
from Merck KGaA.
Incubation
Each flavonoid stock solution was individually prepared as 20 mmol L–1 methanol 
solution. To achieve the desired final concentration during the incubation, an aliquot of the 
stock solution was transferred to a glass tube and dried to remove the organic solvent. In 
this way, an appropriate amount of flavonoid was added to the tube and organic solvent 
was removed from the incubation process as it can interfere with the enzyme activity. Each 
incubation medium contained 100 pmol of human liver microsomes (HLM, amount relates 
to cytochrome P450 enzyme). The pH of the incubation medium was set to physiological 
(7.4) using the potassium phosphate buffer solution (final concentration 50 mmol L–1). The 
reaction was initiated by adding 15 μL of the generating system (GS) consisting of glucose-
-6-phosphate, NADP+, and glucose-6-phosphate dehydrogenase in a ratio of 100:50:2 (V/V/V, 
the final amount in the incubation 15 %). In the negative control (blind test), 15 μL of ultra-
pure water was added to this step instead of GS. The total volume of each incubation 
mixture was 100 μL.
After 15 min of incubation at 37 °C in a water bath with mechanical shaking, the reac-
tion was stopped by adding 60 μL of a mixture of acetonitrile and 25 % hydrochloric acid 
solution (5:1, V/V). The final volume of the incubation mixture, after stopping the reaction, 
was 160 μL and the concentration of flavonoids 125 μmol L–1. After stopping the reaction, 
the incubation mixture was centrifuged at 10,000 rpm for 10 min in a MiniSpin centrifuge 
(Eppendorf AG, Germany). The clear supernatant was transferred to the HPLC vial and 
analyzed by HPLC/MS.
To verify which cytochrome P450 is involved in the metabolism, specific inhibitors 
were used in combination with human liver microsomes, or pure recombinant cytochrome 
P450 was used for analysis replacing HLM. Incubations with recombinant cytochromes 
P450 were conducted using 3 pmol of the enzyme (CYP1A2, CYP2A6, CYP2C8, CYP2C9, 
CYP2C19, CYP2D6 or CYP3A4). Specific inhibitors of cytochromes P450 were 1 μmol L–1 
α-naphthoflavone for CYP1A2, 2 μmol L–1 methoxalen for CYP2A6, 5 μmol L–1 ticlopidin 
for CYP2B6, 50 μmol L–1 quercetin for CYP2C8, 5 μmol L–1 sulfaphenazole for CYP2C9, 10 
μmol L–1 fluconazole for CYP2C19, 2 μmol L–1 ketoconazole for CYP3A4, 2 μmol L–1 quini-
dine for CYP2D6, and 100 μmol L–1 4-methylpyrazole for CYP2E1 (23). The concentration 
of inhibitor refers to the final concentration of the inhibitor in the incubation mixture.
Liquid chromatography coupled with diode array detector and mass spectrometer
Liquid chromatography (LC) coupled with diode array detector (DAD) and mass spec-
trometer (MS) was performed on the Agilent 1200 RR (Agilent Technologies, Germany) LC 
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system coupled to Agilent 6530 Accurate Mass Q-TOF HPLC/MS using electrospray ion-
ization (ESI) interface. The column Poroshell EC-C18 (100 × 3.0 mm i.d., 2.7 μm particle size, 
Agilent) used for separation was set at the temperature of 40 °C. The flow rate was set at 
0.4 mL min–1 and the injection volume was 5 μL. Mobile phase A consisted of water, metha nol 
and formic acid at a ratio of 93:5:2 (V/V/V) whereas the ratio of the same components in 
mobile phase B was 3:95:2 (V/V/V). The gradient was carried out according to the following 
scheme: 0 min, 40 % B; 14–15 min, 80 % B; 16–20 min, 40 % B. The DAD was set at 350 nm. 
Mass spectrometry data collection was performed in MS high-resolution mode, ESI source 
was set to the positive ionization mode and mass spectra were recorded in m/z range of 100 
to 1000. Operating conditions of the MS detector were as follows: drying gas flow 8 L min–1 
at 275.8 kPa nebulizer gas pressure and drying gas temperature at 200 °C, sheath gas flow 
was 11 L min–1 with sheath gas temperature set at 300 °C. The time-of-flight (TOF) analyzer 
was used with the following settings: the voltage of the fragment, skimmer and the octapol 
were 175, 65 and 750 V, resp. All data were collected and processed using Agilent MassHunter 
Workstation Software Program (Agilent Technologies, USA). Identification of the metabolites 
was based on a comparison of exact molecular mass and time of metabolite retention relative 
to the reference standards. Quantification of the detected metabolites was performed on 
the basis of the signals measured by the UV detector.
RESULTS AND DISCUSSION
Development of the HPLC/MS method for the identification and determination of 
flavonoid metabolites
Development of HPLC/MS method for identification and determination of the meta-
bolites of selected flavonoid aglycons was based on the optimization of the HPLC method 
used for the analysis of phenolic acids and flavonoids in various wine and propolis samples, 
published and described in the literature (24, 25). The method was chosen primarily because 
of its wide separation window and mobile phase composition suitable for analysis with the 
MS detector.
The TOF analyzer allowed accurate mass determination and calculation of the mole-
cular formula for the detected ions of flavonoids based on their specific isotopic patterns, 
enabling simple identification in conjugation with the retention time. If metabolite was not 
commercially available, MS/MS spectra were recorded enabling determination of the ring 
in the flavonoid skeleton that undergoes biotransformation. Possible site of reaction could 
be elucidated, although the exact structure of unknown metabolite could not be estab-
lished solely on the basis of MS and MS/MS data. This is in accordance with the previ-
ously reported cases of Tsimogiannis et al. (26) and Cuyckens and Claeys (27).
Fig. 3 shows the methodology of identification and determination of flavonoid meta-
bolites using the example of aromatic hydroxylation to which apigenin is susceptible, gene-
rating luteolin as a metabolite.
Screening of selected flavonoid aglycons that underwent metabolism mediated by human 
liver cytochromes P450 was performed using HLM. Biotransformation was observed in 15 
out of 30 analyzed flavonoids (Table II). Detected metabolites were generated by reactions of 
aromatic hydroxylation and O-demethylation, or a combination of these reactions.
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Fig. 3. The methodology of identification and determination of metabolites. Data used for detection 
of selected flavonoids and their metabolites: retention time, exact mass, molecular formula. An ex-
ample of an apigenin metabolite is given in the figure. The chromatogram in c) refers to the dominant 
metabolite with a retention time of 5.81 min. In b) the peak mass spectrum is shown at 5.81 min, and 
in a) the chromatogram of the separated ion corresponding to the same retention time. Based on 
comparison with pure standard data stored in the database, an unknown metabolite identified as 
luteolin.
In the incubations with 6-hydroxyflavone, a mass change of 2.014545 g mol–1 was re-
corded and the molecular formula C15H12O3 was calculated on the basis of MS data. These 
data indicate the formation of dihydroxychalcone by the opening of the ring C (cleavage 
of the bond O1-C2, see Fig. 2). The change in mass of –15.99491 was also observed, and 
based on MS data calculated molecular formula was C15H12O2. This indicates degradation 
(opening) of the ring C and the formation of monohydroxychalcone. Both of these reac-
tions were observed in incubations without the addition of a generating system, indicating 
a non-enzymatic reaction. Since the same changes observed in the incubations with the 
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added generating system could not be unequivocally attributed to the action of the cyto-
chrome P450 enzyme, and the other changes attributable to the cytochrome P450 activity 
were not related to the original flavonoid 6-hydroxyflavone, the 6-hydroxyflavone results 
were not taken into further consideration.
Determination of flavonoid metabolism mediated by human liver microsomes
In the incubations of 3,7-dihydroxyflavone with human liver microsomes, the forma-
tion of hydroxylated metabolites was detected (Fig. 2a). The main product was identified 
as 3,7,4’-trihydroxyflavone. The second product, present in a much smaller amount, due to 
the lack of commercially available standard, could not be identified, but, based on the MS 
and MS/MS data it was further characterized as the A ring hydroxylated product (either at 
the position 6 or 8).
In the incubations of 7-hydroxyfavone with human liver microsomes, two metabolites 
were detected – hydroxylated products at positions 6 and 8. The main product was identi-
fied as 6,7-dihydroxyflavone (Fig. 2b), and the other product, present in much less quantity, 
was identified as 7,8-dihydroxyflavone.
Two metabolites of acacetin generated by human liver microsomes were detected: api-
genin and luteolin (Fig. 2c). The finding of apigenin and luteolin as metabolism products 
indicates the sequential formation of the metabolites by the action of cytochromes P450. 
First, the demethylation at the position 4’ of ring B occurred, generating apigenin which is 
subsequently hydroxylated at the position 3’ of ring B producing luteolin. Apigenin is the 
most abundant metabolic product, indicating that the acacetin demethylation is the major 
metabolic pathway catalyzed by cytochromes P450. Similarly, in the incubations of apigenin 
with human liver microsomes, the metabolite identified was luteolin (Fig. 2c).
Disometin is metabolized to luteolin in the incubations with human liver microsomes 
as it undergoes O-demethylation at 4’-position of the B ring (Fig. 2d).
In the incubation of flavone with human liver microsomes, metabolite identified as 
4’-hydroxyflavone was detected using a UV detector (Fig. 2e). Additional hydroxylated 
products with different elution times were detected. However, they were generated in 
negligible quantities. Among them, 6-hydroxyflavone and 7-hydroxyflavone have been 
identified.
Galangin was metabolized to kaempferol indicating aromatic hydroxylation of galan-
gin at position 4’ of ring B as a major metabolic pathway (Fig. 2f).
In the incubation of genistein with human liver microsomes, orobol was detected as 
a metabolite (Fig. 2g). The finding of orobol as a metabolic product points to the aromatic 
hydroxylation of the genistein substrate at position 3’ of the ring B.
When hesperetin was incubated with human liver microsomes the formation of a 
metabolite identified as eriodictyol was observed (Fig. 2h). Thus, a major metabolic reac-
tion was O-demethylation of the hesperetin substrate at position 4’ of the ring B.
In the incubation of kaempferol with human liver microsomes (HLM), quercetin was 
identified (Fig. 2i). The finding of quercetin as a metabolic product indicates aromatic hy-
droxylation of kaempferol at position 3’ of the ring B as the major metabolic reaction.
Chrysin generated two metabolites, baicalein and luteolin (Fig. 2j). Both products 
were generated by aromatic hydroxylation: at position 6 of ring A (baicalein) and double 
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aromatic hydroxylation of ring B at positions 3’ and 4’ (luteolin). Although dihydroxylated 
product (luteolin) was observed, monohydroxylated products were not found (e.g., api-
genin), not even in traces. Thus, chrysin biotransformation to luteolin included two con-
secutive hydroxylation reactions without the release of monohydroxylated products from 
the enzyme. In all previous cases where a combined reaction (double hydroxylation or 
demethylation with hydroxylation) was observed, it was found to be sequentially carried 
out over a single hydroxylated or demethylated intermediate. Both metabolites were rep-
resented in approximately equal amounts indicating that none of these metabolic path-
ways catalyzed by cytochrome P450 is favored.
The absence of oxidative metabolism of luteolin was also observed by Nielsen et al. (7), 
although it should be emphasized that the authors in this experiment used rat liver micro-
somes while in our study human liver microsomes were used.
In the incubation of naringenin with human liver microsomes, eriodictyol was identi-
fied as a metabolite (Fig. 2k). Eriodictyol was generated by aromatic hydroxylation of the 
naringenin at the position 3’ of the ring B.
Prunetin was transformed into three metabolites when incubated with human liver 
microsomes (Fig. 2l). The most abundant metabolite was identified as genistein, suggesting 
that O-demethylation is a preferred metabolic pathway. In approximately equal and slightly 
smaller quantities compared to genistein, two aromatic hydroxylated products were gene-
rated by separate pathways, one by hydroxylation at position 3’ of B ring (known as santal), 
and the other at position 6 of the ring A.
In the incubations of sakuranetin with human liver microsomes the formation of 
three metabolites was observed (Fig. 2m). The finding of naringenin and eriodictyol as 
metabolic products indicates the sequential formation of the metabolite by the action of 
cytochrome P450. First, the parent flavonoid sakuranetin is demethylated at the position 7 
of the ring A to form naringenin, and then naringenin is hydroxylated at the position 3’ of 
the ring B, thereby producing eriodictyol. The third product of the sakuranetin metabo-
lism was formed by aromatic hydroxylation at the position 3’ of the ring B, i.e., 5,3’,4’-trihy-
droxy-7-methoxyflavanone was formed. 
Tangeretin generated more than 10 metabolites in the incubations with human liver 
microsomes. The largest number of detected metabolites refers to single and double deme-
thylated tangeretin derivatives in various combinations and at different positions on the 
rings A and B. Most of these metabolites could not be identified because commercially 
available standards of potential metabolites were not available. The absence of single deme-
thylation at ring A, and the absence of double demethylation, could be determined solely 
by LC-MS and LC-MS/MS analysis. Therefore, these products were characterized up to the 
level of reaction type that was catalyzed by cytochrome P450 under experimental condi-
tions used. However, the two major metabolites, most commonly found in tangeretin 
 incubations with HLM, were indirectly identified based on data obtained by LC-MS/MS 
analysis (Fig. 2n). MS/MS spectra showed a mass loss of 14.01564 g mol–1 on the ring B with 
tR of 9.52 min. Since only one methoxy group at position 4’ is present in the tangeretin ring 
structure B, this metabolite is characterized as a 4’-demethylated tangeretin derivative, i.e., 
4’-hydroxy-5,6,7,8-tetramethoxyflavone. Similarly, the structure of the second most com-
monly found metabolite detected at tR = 7.83 min showed a mass increase of 1.9799 g mol–1 
that is located on ring B (based on MS/MS analysis), indicating demethylation at the 4’ 
position and hydroxylation at the positions 2’ or 3’. Based on the literature data (Table I), 
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as well as other results presented in this paper, if a flavonoid is already hydroxylated at the 
position 4’, the subsequent aromatic hydroxylation will occur at the position 3’ of the ring 
B. Therefore, the metabolite at tR = 7.83 min was characterized as the most probable 4’-de-
methylated and 3’-hydroxylated tangeretin derivative, i.e., 3’,4’-dihydroxy-5,6,7,8-tetrame-
thoxyflavone. This metabolite is most likely sequentially formed by aromatic hydroxyl-
ation at the position 3’ of the ring B after primary O-demethylation at the position 4’ of the 
ring B.
Determination of cytochromes P450 involved in the metabolism of flavonoid aglycons
Flavonoids that underwent metabolic changes in human liver microsomes (HLM) in-
cubations were further investigated in incubations with individual recombinant cyto-
chromes P450. The experiments using recombinant cytochromes P450 were only conducted 
for those flavonoids that showed metabolite formation in the amount of at least 10 % (m/m) 
compared to the amount of substrate in the HLM experiments. Therefore, the metabolism 
mediated by individual recombinant cytochrome P450 is reported for the following 10 
flavonoid aglycons: 3,7-dihydroxyflavone, 7-hydroxyflavone, acacetin, apigenin, flavone, 
galangin, kaempferol, naringenin, sakuranetin and tangeretin (Table II).
Incubations with individual recombinant cytochrome P450s indicate that the 3,7-di-
hydroxyflavone metabolism is mediated by CYP1A2 enzyme. This enzyme was the only 
one involved in the metabolic conversion of 3,7-dihydroxyflavone but did not catalyze the 
major metabolic reaction of aromatic hydroxylation at the 4’ position of the B ring observed 
in the HLM experiments (Fig. 2a), rather the secondary hydroxylation reaction on the ring 
A at positions 6 or 8, producing the only metabolite 3,6,7-trihydroxyflavone or 3,7,8-trihy-
droxyflavone (tR = 8.95 min). The major metabolic conversion of 3,7-dihydroxyflavone to 
3,7,4’-trihydroxyflavone was not catalyzed by any of the enzymes tested.
7-Hydroxyflavone metabolism (Fig. 2b) is mediated by CYP1A2, CYP2D6 and CYP3A4. 
Both hydroxylated metabolites (6,7-dihydroxyflavone and 7,8-dihydroxyflavone), observed 
in the HLM experiment, were generated only by CYP3A4. In the incubations with CYP1A2 
and CYP2D6, only 6,7-dihydroxyflavone was detected, the major metabolite which was 
found in the HLM experiments. Although CYP3A4 catalyzed both metabolic pathways ob-
served in the HLM experiment, the overall contribution is smaller than that of CYP1A2 and 
CYP2D6. Based on these results, it can be concluded that all three cytochrome P450 enzymes 
are equally important for the oxidative metabolism of 7-hydroxyflavone.
Acacetin biotransformation (Fig. 2c) is mediated by CYP1A2 and CYP2D6 enzymes. 
In the experiment with CYP1A2, both metabolic products were observed similarly to the 
HLM incubations; namely, apigenin and luteolin, while CYP2D6 catalyzed only the de-
methylation of acacetin producing apigenin. In both experiments, the main product of 
apigenin was generated in approximately equal amounts.
Apigenin metabolism (Fig. 2c) is mediated exclusively by CYP1A2 enzyme. Just as in 
the experiments with HLM, incubations with CYP1A2 resulted in the formation of luteo-
lin, suggesting that this enzyme catalyzes the aromatic hydroxylation of apigenin at the 
position 3’ of the ring B.
Incubations with individual recombinant cytochrome P450s indicate that the flavone 
(Fig. 2e) metabolism is mediated by the CYP1A2 enzyme. Similarly to the HLM experiment, 
the dominant metabolite was 4’-hydroxyflavone (tR = 8.59 min). Several other hydroxylated 
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products with different elution times were detected using MS detector, but in negligible 
quantities. This also applies to the peak at tR = 6.76 min on the chromatogram which was 
characterized as a double hydroxylated flavone derivative. The finding of 4’-hydroxyflavone 
as the main product in CYP1A2 incubation suggests that aromatic hydroxylation of the 
flavone substrate at the 4’ position of the B ring is catalyzed by this enzyme.
CYP2C19 and CYP2D6 enzymes were found to be responsible for galangin metabo-
lism (Fig. 2f). Just as in the experiments with HLM, incubations of CYP2C19 and CYP2D6 
showed the formation of one metabolite – kaempferol, suggesting that this enzyme cata-
lyzes the aromatic hydroxylation of galangin at the position 4’ of the ring B. It should be 
noted that in both experiments, small amounts of kaempferol were produced in both cases, 
much less than in HLM experiments. Kaempferol is metabolized by CYP1A2 enzyme (Fig. 2i). 
In incubations with CYP1A2, similar to the HLM experiment, the only detected metabolite 
was quercetin (tR = 5.60 min).
Incubations with individual recombinant cytochrome P450s indicate that the metabolism 
of naringenin is mediated by CYP1A2 enzyme (Fig. 2k). In the incubations with CYP1A2, 
similar to the HLM experiment, the only detected metabolite was hydroxylated eriodictyol 
(tR = 3.90 min).
CYP1A2 and CYP3A4 were found to be major enzymes responsible for the metabolism 
of the sakuranetin (Fig. 2m). Two metabolites were detected in CYP1A2 incubations: 
5,3’,4’-trihydroxy-7-methoxyflavanone (tR = 7.77 min) and naringenin (tR = 5.53 min). The find-
ing of these two metabolites suggests that CYP1A2 catalyzes the conversion of sakuranetin 
through O-demethylation and aromatic hydroxylation as determined by the HLM experi-
ments, but their ratios suggest that, unlike the HLM experiment, pure enzyme CYP1A2 
 favored aromatic hydroxylation of the sakuranetin at the position 3’ of the ring B when 
compared to O-demethylation at the position 7 of the ring A. In the incubations with CYP3A4 two 
 metabolites were also detected: 5,3’,4’-trihydroxy-7-methoxyflavanone at tR = 7.75 min, and 
an unknown compound with mass difference of –2,0155 g mol–1 compared to the substrate 
sakuranetin, and molecular formula C16H12O5 (tR = 11.74 min). Moreover, this was the predo-
minant metabolic product in CYP3A4 incubations, while the 3’-hydroxylated derivative of 
sakuranetin was produced in a somewhat smaller amount. Aromatic hydroxylation of 
sakuranetin at the position 3’ of the ring B is favored compared to the O-demethylation at 
position 7 of the ring A by both CYP3A4 and CYP1A2. The latter metabolic pathway was not 
catalyzed by CYP3A4 at all. It has to be noted that the sequential aromatic hydroxylation of 
naringenin, the primary metabolite of sakuranetin in the HLM experiments, and its conver-
sion to the eriodictyol was not catalyzed by any of the enzymes tested.
Tangeretin metabolism was mediated by CYP1A2, CYP2D6, and CYP3A4 enzymes 
(Fig. 2n). Based on the amount of metabolite produced, it can be concluded that the most 
important enzymes are CYP1A2 and CYP3A4. However, the role of CYP1A2 is more im-
portant as it catalyzes tangeretin’s major metabolic reaction observed in the HLM experi-
ment, i.e., 4’-demethylation followed by hydroxylation at the position 3’ of the ring B (tR = 
7.81 min). CYP3A4 catalyzed only the reaction of 4’-demethylation of tangeretin (tR = 9.40 
min), without further conversion to the 3’-hydroxylated product. However, the 4’-demeth-
ylated derivative was just the second most commonly found metabolite with CYP3A4, 
while the major metabolite was a single-demethylated derivative of tangeretin at the ring 
A (tR = 10.85 min). CYP2D6 catalyzed only the conversion of tangeretin to the 4’-demethyl-
ated derivative (tR = 9.46 min) in smaller amounts.
554
G. Benković et al.: Screening of flavonoid aglycons’ metabolism mediated by the human liver cytochromes P450, Acta Pharm. 69 (2019) 
541–562.
 
Fig. 4. Inhibition assays for the reactions: a) 3,7-dihydroxyflavone → 3,7,4'-trihydroxyflavone and b) 
sakuranetin → naringenin (N) + eriodictyol (E). Black columns represent the percentage of 
metabolite/s generated in control without the specific inhibitor of cytochrome P450 and grey columns 
with the addition of the inhibitor. Results represent the mean ± standard error (n = 3).
None of the recombinant cytochromes P450 used in the present study catalyzed bio-
transformation of 3,7-dihydroxyflavone and sakuranetin. As the metabolism of 3,7-dihy-
droxyflavone and sakuranetin was observed in experiments with the human liver micro-
somes, further experiments were conducted on the human liver microsomes using 
specific inhibitors of cytochromes P450. The reaction of biotransformation of 3,7-dihydroxy-
flavone to 3,7,4’-trihydroxyflavone was inhibited in the incubations with the specific CYP2E1 
inhibitor (4-methylpyrazole, 80 % inhibition, p < 0.05) (Fig. 4).
In the experiment with sakuranetin, the inhibition of the combined reaction of O-de-
methylation of sakuranetin at the 7-position of ring A and of the aforementioned aromatic 
hydroxylation resulting in naringenin production was observed, when specific inhibitors 
of cytochromes P450 were used. The observed amounts of metabolites produced were 
determined by the UV detector. The reaction can be schematically written as: sakuranetin 
→ naringenin → eriodictyol (Fig. 2m). Obtained results indicate a moderate and statistically 
significant (p < 0.05) inhibition of observed metabolic response in incubations with the 
specific CYP2E1 inhibitor. Moderate inhibition of 15 % was observed in incubations with 
the specific CYP2C8  inhibitor (quercetin, p < 0.05) for the total amount of metabolites 
 produced, but not for  individual metabolites. Given the very slight inhibition indicated by 
the results for CYP2C8 and the fact that incubations with the recombinant enzyme did not 
indicate the metabolism of sakuranetin, this enzyme cannot be regarded as the most  important 
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one for the  metabolism of sakuranetin. However, it can be concluded that among the examined 
cytochromes P450, CYP2E1 enzyme is only important for catalyzing the observed reaction 
of sakuranetin → naringenin → eriodictyol, although the inhibition of 50 % suggests that 
there could be other cytochromes P450 that may be, to a certain extent, responsible for this 
metabolic conversion (not analyzed in this study).
Metabolism of flavones
Acacetin undergoes demethylation and hydroxylation reactions in which CYP1A2 and 
CYP2D6 enzymes are involved. Androutsopoulos et al. (6) conducted experiments on recom-
binant CYP1A1 and CYP1B1 enzymes. These enzymes have been investigated primarily 
because of their potential role in carcinogenesis, but their share in healthy liver metabolism 
of xenobiotics is virtually negligible (28). Because of all this, it can be said that our study is 
the first one to describe the metabolism of acacetin mediated by cytochromes P450, which 
have a relevant meaning for the general population. The results of our study indicate that 
the oxidative metabolism of acacetin is characterized by two metabolic reactions in which two 
metabolites are formed: apigenin and luteolin. This is a combined reaction of O-demethyla tion 
followed by sequential aromatic hydroxylation and can be schematically shown as follows: 
acacetin → apigenin → luteolin (Fig. 2c). A complete combined reaction is catalyzed by human 
liver microsomes and CYP1A2, while CYP2D6 catalyzes only the reaction of demethylation 
of acacetin to produce apigenin. The results of our study suggest that oxidative metabolism 
of apigenin is characterized by an aromatic hydroxylation in which luteolin metabolite is 
formed. This reaction is catalyzed by human liver microsomes and CYP1A2. Androutsopoulos 
et al. (6) determined the same type of metabolic reaction of apigenin using the CYP1A1 and 
CYP1B1 enzymes. Although two products were detected in their study, only one was charac-
terized as scutellarein. Scutellarein is the product of the aromatic hydroxylation at position 
3 of apigenin, and it was not detected in the herein presented study. Lack of scutellarein as 
a metabolic product can be attributed to cytochromes P450 used in research due to different 
objectives of the studies (enzymes involved in carcinogenesis versus enzymes expressed in 
healthy population; vide supra).
Diosmetin undergoes O-demethylation reaction at position 4’ of the ring B generating 
luteolin (Fig. 2d). This reaction is catalyzed by human liver microsomes (HLM), and since 
less than 10 % (m/m) of the metabolite is produced in comparison to the substrate concen-
tration, the metabolism of diosmetin was not further characterized. The results obtained 
in this study agree with those previously published by Androutsopoulos et al. who con-
ducted in vitro experiments with recombinant cytochrome P450 and MCF-7 breast cancer 
cell lines (10) as well as cell lines of breast adenocarcinoma MDA-MB 468 and normal 
breast tissue MCF-10A (29) showing that the main route of diosmetin metabolism was the 
same as suggested in this study. Authors of aforementioned studies (10, 29) further deter-
mined that CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A5 
are not responsible for this reaction and that the major role in the oxidative metabolism of 
diosmetin is attributed to CYP1A2 and, to a lesser extent, CYP3A4.
Oxidative metabolism of flavone is characterized by aromatic hydroxylation that gene-
rates a metabolite, identified as 4’-hydroxyflavone (Fig. 2e). Minor products of aromatic hydroxy-
lation were detected only by MS detector, but in relatively negligible quantities.  The finding 
of 4’-hydroxyflavone as the main metabolite product suggests that aromatic hydroxylation 
556
G. Benković et al.: Screening of flavonoid aglycons’ metabolism mediated by the human liver cytochromes P450, Acta Pharm. 69 (2019) 
541–562.
 
of unsubstituted flavone is mediated by a cytochrome P450 enzyme, namely, CYP1A2. Meta-
bolism of flavone has not been described in the available literature so far, so the results 
 obtained in this paper are the first reported data on its metabolism.
Metabolism of 7-hydroxyflavone is characterized by two metabolic reactions in which 
two metabolites are formed: 6,7-dihydroxyflavone and 7,8-dihydroxyflavone (Fig. 2a). These 
are hydroxylated metabolites generated in incubations with human liver microsomes and 
CYP3A4. In the incubations with CYP1A2 and CYP2D6, only 6,7-dihydroxyflavone, the major 
metabolite in the HLM experiments, was detected. Although CYP3A4 catalyzed both meta-
bolic pathways observed in the HLM experiment, the overall contribution to the metabolism 
was somewhat lower than that of CYP1A2 and CYP2D6. The metabolism of 7-hydroxyflavone 
has not been described in the available literature so far, so the results obtained in this paper 
are the first report on its metabolism.
Chrysin undergoes two oxidative reactions in which two metabolites are formed: baica-
lein and luteolin (Fig. 2j). Baicalein is generated by the aromatic hydroxylation at the position 
6 of the ring A, and dual aromatic hydroxylation at the positions 3’ and 4’ of the ring B results 
in the formation of luteolin. This reaction is catalyzed by HLM, and since less than 10 % 
(m/m) of metabolites are produced compared to the substrate concentration, the chrysin me-
tabolism was not further characterized.
Most of the detected tangeretin metabolites in human liver microsomes incubations 
could not be identified due to the lack of appropriate standards. The majority of detected 
metabolites were single or double demethylated tangeretin derivatives. As tangeretin pos-
sesses five methoxy groups, different methoxy groups could undergo demethylation reac-
tions, resulting in various metabolites all of which were detected in smaller amounts. How-
ever, the two main metabolites, most commonly found in tangeretin incubations with HLM, 
were indirectly identified on the basis of data obtained by LC-MS/MS analysis. These were 
4’-hydroxy-5,6,7,8-tetramethoxyflavone and 3’,4’-dihydroxy-5,6,7,8-tetramethoxyflavone. 
 Major metabolites were formed sequentially by primary O-demethylation at the position 4’ of 
the ring B followed by aromatic hydroxylation at the position 3’ of the ring B: tangeretin → 
4’-hydroxy-5,6,7,8-tetramethoxyflavone → 3’,4’-dihydroxy-5,6,7,8-tetramethoxyflavone (Fig. 
2n). Incubations with individual recombinant cytochrome P450s indicate that tangeretin 
metabolism is mediated by CYP1A2, CYP2D6, and CYP3A4 enzymes. Based on the amount 
of metabolites produced, it can be concluded that the most important role is attributed to 
CYP1A2 and CYP3A4. CYP1A2 is the most important enzyme for the oxidative metabolism 
of tangeretin since it catalyzed its major metabolic reaction observed in the HLM experi-
ments. The results obtained are well related to the already published tangeretin metabolism 
data (Table I). The main metabolite with the highest content, in this case, was 4’-hydroxy-
-5,6,7,8-tetramethoxyflavone. Experiments with recombinant cytochrome P450 showed that 
enzymes CYP1A2, CYP3A4, and CYP2D6 were involved in the oxidative metabolism of 
tangeretin, but it was not accurately determined which enzyme was responsible for each 
individual metabolic reaction. As in this study, it has been shown that the major enzyme 
CYP1A2 is responsible for demethylation at the position 4’ of the ring B, as well as post 
 hydro xylation at position 3’ of the ring B of the demethylated product. The same biotrans-
formation was observed with CYP3A4, but to a lesser extent. The results for CYP3A4 are 
partially in discrepancy with the fact that no further oxidation of the 4’-demethylated product 
in CYP3A4 incubations has been observed in this study. However, Breinholt et al. (12) 
 observed oxidation of the 4’-demethylated product in low quantities. This minor difference 
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between the herein presented and literature data could be attributed to differences in expe-
rimental conditions. It is particularly important to note that the quantity of cytochrome P450 
used in their study is not disclosed. Finally, we can conclude that the results presented herein 
confirmed the main route of tangeretin metabolism mediated by human liver cytochrome 
P450 and the major role of CYP1A2 in this biotransformation.
Metabolism of flavonols
In this paper 10 flavonoids belonging to the flavonol group were tested. For seven of 
them, information about metabolism can be found in the literature (galangin, isorhamnetin, 
kaempferol, quercetin, myricetin, morin, and tamarixetin) (Table I). For the remaining three 
tested flavonoids from this group (3,6-dihydroxyflavone, 3,7-dihydroxyflavone, and rham-
netin), this is the first report on cytochrome P450 mediated metabolism. Metabolism medi-
ated by human liver cytochrome P450 under experimental conditions described in this paper 
was not recorded for the following flavonols: 3,6-dihydroxyflavone, isorhamnetin, quercetin, 
myricetin, morin, rhamnetin, and tamarixetin. This result confirmed data published by 
Nielsen et al. (7) who also determined the absence of metabolism of isorhamnetin, quercetin, 
myricetin, and morin in incubation with rat cytochromes P450.
While in our study tamarixetin metabolism was not detected, its metabolism was noted 
in the previous studies by Nielsen et al. (7) and Breinholt et al. (8) who determined the meta-
bolic conversion of tamarixetin into quercetin by the reaction of demethylation at the posi-
tion 4’ of the ring B mediated by the enzyme CYP1A2. When comparing the enzyme sys-
tems, HLM and recombinant cytochromes P450, two evident differences in the studies have 
been noticed. Breinholt et al. (8) used markedly greater enzyme concentration (up to 30-fold) 
relative to incubation in our study. At the same time concentrations of the enzyme in human 
liver microsomes incubations were not reported.
Incubations with individual recombinant cytochrome P450s indicate that the 3,7-dihy-
droxyflavone metabolism is mediated by CYP1A2 enzyme. This enzyme was the only tested 
enzyme involved in the metabolic conversion of 3,7-dihydroxyflavone but it did not catalyze 
the major metabolic reaction – aromatic hydroxylation at the 4’ position of the B ring observed 
in the HLM experiments. However, CYP1A2 did catalyze the secondary hydroxylation reac-
tion on the ring A at the positions 6 or 8, forming only one metabolite, 3,6,7-trihydroxyflavone 
or 3,7,8-trihydroxyflavone. The major metabolic conversion of 3,7-dihydroxyflavone to 3,7,4’-tri-
hydroxyflavone was not catalyzed by any of the enzymes tested. Based on the results of the 
inhibition assays with specific cytochrome P450 inhibitors, the major reaction was attributed 
to the CYP2E1 enzymes. The results of the 3,7-dihydroxyflavone metabolism are particularly 
interesting because it is the only example in which purified enzyme (CYP1A2) catalyzed the 
secondary reaction to a greater extent when compared to the major reaction catalyzed by HLM.
Oxidative metabolism of galangin is characterized by a metabolic reaction in which a 
kaempferol metabolite is formed. This reaction is catalyzed by human liver microsomes, 
CYP2C19 and CYP2D6. Under the experimental conditions, small amounts of kaempferol 
were produced in pure enzyme incubations, much less when compared to the HLM ex-
periment. Otake and Walle (13) found that CYP1A2 had a dominant role in this metabolic 
conversion and CYP2C9 to some extent. Based on the small differences in the experiment 
conditions, it is not possible to find a clear explanation for the observed difference when 
comparing the results to our study. Otake and Walle (13) investigated galangin metabolism 
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with three relevant recombinant pure enzymes CYP1A2, CYP2C9, and CYP3A4. Although 
the main role of CYP1A2 has been found, based on inhibition assays using specific inhibi-
tors where the metabolism mediated by HLM was inhibited by 40 % with a specific CYP1A2 
inhibitor, the authors determined that other specific cytochrome P450 enzymes may be 
involved in this metabolism as well.
Kaempferol metabolism is characterized by aromatic hydroxylation at the position 3’ 
of the ring B in which quercetin is formed. This metabolic conversion was catalyzed by 
human liver microsomes and CYP1A2. Kaempferol metabolism has been described in the 
literature in the work of Breinholt et al. (8) and the results of our study are fully consistent 
with these results.
Metabolism of isoflavones
In this study, two representatives of isoflavones were tested: genistein and prunetin. 
For both flavonoids, oxidative metabolism mediated by human cytochrome P450 is well 
described in the literature and particularly well documented for genistein (Table I).
The results of this study indicate that the oxidative metabolism of genistein is character-
ized by a single metabolic reaction in which an orobol metabolite is formed by aromatic 
hydroxylation at the position 3’ of the ring B. This reaction is catalyzed by human liver mi-
crosomes (HLM), and since less than 10 % (m/m) of metabolites is produced in comparison 
to the substrate concentration, the metabolism of genistein was not further characterized. 
The results obtained in this study agree with the previously published literature; the afore-
mentioned reaction is the dominant reaction reported in the literature (14–19).
Oxidative metabolism of the prunetin is characterized by three metabolic reactions in 
which the following metabolites are formed: genistein, 6-hydroxyprunetin and 3’-hy-
droxyprunetin. O-demethylation is a somewhat preferred metabolic pathway of prunetin 
biotransformation by cytochromes P450. However, it should be noted that the remaining 
two hydroxylated products were found in similar amounts, which were lower when com-
pared to the amount of genistein. All three reactions are catalyzed by human liver micro-
somes, to the extent less than 10 % (m/m); consequently, the metabolism of the prunetin was 
not further characterized. The results obtained in this study agree with the previously 
published research of Hua et al. (17), who described the observed metabolic reaction as a 
very rapid conversion of prunetin to genistein, but at the same time did not report any 
other metabolic pathway of prunetin. The largest difference between the two studies was 
again in the incubation enzyme concentration; Hua et al. used markedly higher concentra-
tions, about 3 times greater than in the HLM experiments in our study.
Metabolism of flavanones
In this study, six flavonoids belonging to the flavanone group were subjected to cyto-
chrome P450 catalyzed reactions. In the primary scientific literature, only hesperetin and 
naringenin metabolism is described to some extent (7, 8, 20). For the remaining four exam-
ined flavonoids from this group (flavanon, pinocembrin, pinocembrin-7-methylether and 
sakuranetin), this is the first report on cytochrome P450 mediated metabolism.
Hesperetin undergoes O-demethylation reaction at the position 4’ of the ring B gener-
ating eriodictyol. This reaction is catalyzed by human liver microsomes to a lesser extent 
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(less than 10 %, m/m) and was not further characterized. The results obtained in this study 
agree with those previously published by Nielsen et al. (7) and Breinholt et al. (8) who con-
ducted incubations with rat liver microsomes, HLM and recombinant CYP1A2 showing 
that the major route of hesperetin metabolism was identical to the one suggested in our 
research. Authors of the aforementioned studies (7, 8) also determined that CYP2C9, 
 CYP2D6 and CYP3A4 are not responsible for this reaction, and that the major role in hesperetin 
oxidative metabolism is attributed to CYP1A2. These two studies as well as ours are contrary 
to the results of Doostdar et al. (20) who did not detect metabolism of hesperetin mediated 
by cytochromes P450, which is most likely due to too low concentrations of flavonoids used 
in incubation mixtures (up to 1.5 μmol L–1).
Naringenin is biotransformed to eriodictyol in the reaction of aromatic hydroxylation 
at the position 3’ of the ring B. This reaction was observed in experiments with human 
liver microsomes, and attributed to CYP1A2. The result of the metabolism of naringenin 
obtained in this study agrees with the literature data with regard to the reaction catalyzed 
by human liver cytochrome P450, in which the main metabolite produced is eriodictyol. 
Conclusions regarding the specific cytochrome P450 enzymes dominantly responsible for 
the catalysis of this reaction are, however, to some extent different from those published. 
While Breinholt et al. (8) found that CYP1A2 had a dominant role in this metabolic conver-
sion, our study showed that CYP3A4 did not metabolize naringenin under experimental 
conditions and that CYP1A2 was only a secondary enzyme responsible for the observed 
naringenin metabolism. The enzyme dominantly responsible for this metabolic reaction 
was not found and was not among the tested group of enzymes (CYP1A2, CYP2A6, CYP2C8, 
CYP2C9, CYP2C19, CYP2D6 and CYP3A4).
The results of the herein presented study suggest that there are two metabolic path-
ways of sakuranetin biotransformation mediated by the human liver cytochromes P450. 
Sakuranetin is metabolized to naringenin, eriodictyol, and 5,3’,4’-trihydroxy-7-methoxyfla-
vanone; enzymes responsible for the metabolism are CYP1A2 and CYP3A4. In the incuba-
tions with CYP1A2 two metabolites were detected: 5,3’,4’-trihydroxy-7-methoxyflavanone 
and naringenin. The finding of these two metabolites suggests that CYP1A2 catalyzes the 
conversion of sakuranetin through O-demethylation and aromatic hydroxylation as deter-
mined by the HLM experiments but their ratios suggest that, unlike the HLM experiment, 
CYP1A2 enzyme favored aromatic hydroxylation of the sakuranetin at the position 3’ of 
the ring B vs. O-demethylation at the position 7 of the ring A. In the incubations with 
CYP3A4, two metabolites were detected: again 5,3’,4’-trihydroxy-7-methoxyflavanone and 
an unknown compound with molecular formula C16H12O5. Moreover, 5,3’,4’-trihydroxy-
-7-methoxyflavanone was the predominant metabolic product in CYP3A4 incubations, 
while the 3’-hydroxylated derivative of sakuranetin was produced in a somewhat smaller 
amount. This metabolite was also found in HLM incubations, but in much smaller amounts 
compared to other metabolites, suggesting that this third metabolic pathway of sakurane-
tin metabolism is mediated by cytochromes P450. Interestingly, the sequential aromatic 
hydroxylation of naringenin, the primary metabolite from the HLM experiment, and its 
conversion to the eriodictyol was not observed. Inhibition assays with specific cytochrome 
P450 inhibitors showed that CYP2E1 was the only significant enzyme involved in catalysis 
of the reaction sakuranetin → naringenin → eriodictyol. The sakuranetin metabolism has 
not been described in the available literature so far, so the results obtained in this paper 
are the first known data on its metabolism.
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Hydroxylation of flavones is catalyzed by human cytochrome P450 at position 3’ and 
4’ of ring B, with position 4’ being favored on unsubstituted ring B. Hydroxylation is also 
possible at positions 6 and 8 of the ring A. Aromatic hydroxylation of an unsubstituted 
flavone is preferred at the position 4’ of the ring B, but that hydroxylation is also possible 
at other positions in the flavone structure. O-demethylation of the methoxy group in fla-
vone is favored at position 4’ of ring B, although tangeretin is an example for which de-
methylation is also possible on ring A. The enzyme dominantly responsible for the ob-
served metabolic reactions of the flavone class is CYP1A2. Although the majority of the 
flavonoids from flavones class were examined (eleven), half of them did not show oxidative 
metabolism mediated by cytochromes P450.
Similarly to flavones, flavonols undergo aromatic hydroxylation catalyzed by human 
liver cytochrome P450 at the ring B, positions 3’ and 4’, whereas position 4’ is favored on 
unsubstituted ring B. However, in the case of 3,7-dihydroxyflavone metabolism, it can be 
seen that hydroxylation is also possible on ring A at positions 6 and 8, position 6 being 
favored in relation to position 8. The presence of two or more hydroxyl groups on the B 
ring of the flavonols appears to prevent further metabolism mediated by human liver cyto-
chromes P450. Although several mono-methylated flavonols representatives were tested, 
O-demethylation was not observed in this flavonoid class of compounds. The enzyme that 
is dominantly responsible for the observed flavonols metabolism is CYP1A2, but its role is 
not expressed to such a degree as in the case of flavones, whereas in the case of 3,7-dihy-
droxyflavone it is shown that some other specific cytochrome P450 (i.e., CYP2E1) has a 
more important role in its metabolism.
A sample of the examined isoflavones in this study is too small to extract general 
conclusions about their oxidative metabolism mediated by human liver cytochrome P450, 
but it can be noted that results are consistent with the genistein and prunetin data already 
reported in the literature. Likewise, the observed aromatic hydroxylation at the position 3’ 
of the ring B of genistein and prunetin fits well into overall results for tested flavonoids, 
especially for the flavone group structurally closest to isoflavones. Thus, isoflavone ring B 
hydroxylation is favored at position 3’, if a hydroxyl group at position 4’ is already present 
in the structure. In the example of prunetin it is shown that O-demethylation is possible at 
position 7 of the ring A and that aromatic hydroxylation is possible at position 6 of the ring 
A in isoflavone skeleton.
Flavanone results were in good agreement with those reported for hesperetin and 
naringenin. The observed aromatic hydroxylation at the position 3’ of the ring B of narin-
genin and sakuranetin fits well with the overall results for tested flavonoids. Flavanone 
undergoes hydroxylation of the ring B that is favored at the position 3’, if a hydroxyl group 
at the position 4’ is already present in the structure. The importance of this hydroxyl group 
for the oxidative metabolism of flavanone is further underlined by the absence of metabo-
lism of flavanone pinocembrin and pinocembrin-7-methylate having an unsubstituted 
ring B. In the example of hesperetin and sakuranetin it is shown that O-demethylation is 
possible at the position 4’ of the ring B and at the position 7 of the ring A. CYP1A2 is 
dominantly responsible for observed flavanone metabolism, whereas other specific cyto-
chrome P450 (i.e., CYP2E1 or CYP3A4) plays an important role in the metabolism of 
sakuranetin and naringenin.
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The overall conclusion of this study is that flavonoid aglycons undergo two types of 
oxidative reactions: aromatic hydroxylations and O-demethylations catalyzed mainly by 
cytochrome P450 1A2. Aromatic hydroxylation is favored at the position 4’ of B ring, and 
in 3’ if a hydroxyl group at the position 4’ is already present in the structure. Moreover, the 
presence of two or more hydroxyl groups on the B ring of the flavanols appears to prevent 
further metabolism mediated by human liver cytochromes P450. O-demethylation of the 
methoxy group is favored at position 4’ of ring B. These results, to some extent, contribute 
to the understanding of the metabolism of constituents found in antioxidant dietary sup-
plements and their possible interactions with other xenobiotics, i.e., interactions with 
drugs metabolized by the same cytochromes P450 as flavonoids.
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